Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IDEAYA BIOSCIENCES, INC.

(IDYA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/30/2021 12/01/2021 12/02/2021 12/03/2021 12/06/2021 Date
22(c) 21.37(c) 22.51(c) 22.06(c) 20.95(c) Last
1 010 241 280 686 254 948 191 515 229 730 Volume
-1.48% -2.86% +5.33% -2.00% -5.03% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 34,0 M - -
Net income 2021 -43,5 M - -
Net cash position 2021 374 M - -
P/E ratio 2021 -16,9x
Yield 2021 -
Sales 2022 39,8 M - -
Net income 2022 -56,3 M - -
Net cash position 2022 318 M - -
P/E ratio 2022 -14,5x
Yield 2022 -
Capitalization 806 M 806 M -
EV / Sales 2021 12,7x
EV / Sales 2022 12,3x
Nbr of Employees 83
Free-Float 93,4%
More Financials
Company
IDEAYA Biosciences, Inc. is a synthetic lethality-focused precision medicine company. The Company focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The CompanyÔÇÖs product candidate is IDE196, a protein kinase C (PKC), inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes multiple... 
Sector
Biotechnology & Medical Research
Calendar
12/07 | 08:30amSpecial Situation
More about the company
Ratings of IDEAYA Biosciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about IDEAYA BIOSCIENCES, INC.
07:50aIdeaya Biosciences Says Metastatic Uveal Melanoma Treatment Demonstrated Tumor Shrinkag..
MT
07:01aIDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib..
PR
11/30IDEAYA Biosciences to Participate in Investor Conferences in December 2021
PR
11/29IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1/2 Trial of Darov..
PR
11/15IDEAYA BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
11/15IDEAYA BIOSCIENCES : Reports Third Quarter 2021 Financial Results and Provides Business Up..
PU
11/15IDEAYA Biosciences Net Loss Narrows After Sales Increase in Q3
MT
11/15IDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Busi..
PR
11/15IDEAYA Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
11/01IDEAYA Biosciences to Participate in Investor Conferences in November 2021
PR
10/18IDEAYA BIOSCIENCES : Names Michael White as Chief Scientific Officer
MT
10/18IDEAYA BIOSCIENCES : Appoints Michael White, Ph.D., as Chief Scientific Officer
PR
10/18IDEAYA Biosciences Appoints Michael White as Chief Scientific Officer
CI
09/23IDEAYA BIOSCIENCES : Stifel Starts IDEAYA Biosciences at Hold With $27 Price Target
MT
09/20IDEAYA BIOSCIENCES, INC.(NASDAQGS : IDYA) added to S&P Biotechnology Select Industry Index
CI
More news
News in other languages on IDEAYA BIOSCIENCES, INC.
11/15IDEAYA Biosciences réduit sa perte nette après une augmentation des ventes au troisième..
09/08VENTE D'INITIÉS : Ideaya Biosciences
08/10Earnings Flash (IDYA) IDEAYA BIOSCIENCES annonce un chiffre d'affaires de 8,8 millions ..
07/08IDEAYA Biosciences propose une offre à 17,25 dollars par action et prévoit un produit b..
07/07Les actions américaines terminent en hausse après le compte rendu de la Fed ; le S&P 50..
More news
Analyst Recommendations on IDEAYA BIOSCIENCES, INC.
More recommendations
Chart IDEAYA BIOSCIENCES, INC.
Duration : Period :
IDEAYA Biosciences, Inc. Technical Analysis Chart | IDYA | US45166A1025 | MarketScreener
Technical analysis trends IDEAYA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 20,95 $
Average target price 30,56 $
Spread / Average Target 45,8%
EPS Revisions
Managers and Directors
Yujiro S. Hata President, Chief Executive Officer & Director
Paul A. Stone Chief Financial Officer & Executive Vice President
Timothy M. Shannon Chairman
Matthew Maurer VP, Head-Medical Affairs & Clinical Oncology
Michael Anthony White Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
IDEAYA BIOSCIENCES, INC.49.64%806
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
IQVIA HOLDINGS INC.46.84%50 262
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-42.48%23 888